Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares saw a handy gain on Tuesday after the firm announced positive data from a couple of its trials. Specifically, Xenon presented data from its XEN901 Phase 1 clinical trial and from its XEN1101 Phase 1 clinical trial at the Eilat Conference on New Antiepileptic Drugs and Devices in Madrid, Spain.
Are Xenon Pharmaceuticals Shares Making a Run?
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться